



PREDICTMEDIX

AI-Powered Rapid Health Screening Solutions for Workplace Safety

PREDICTMEDIX.COM

CSE : PMED OTCQB : PMEDF



Forward Looking Statements Disclaimer


This presentation may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law. Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time."



Predictmedix Overview

Predictmedix is a leading provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations – powered by a proprietary artificial intelligence (AI) – use multispectral cameras to analyze physiological data patterns and identify symptoms of COVID-19, drug or alcohol impairment and mental illnesses.

- **Contactless, Non-Invasive Screening:** Rapid screening process, similar to walking through a metal detector, utilizes AI to assess unique physiological patterns of diseases or impairments in seconds – maintaining workplace productivity.
- **Significant Addressable Market:** Safe Entry Stations have been successfully deployed at offices, long-term care centers, industrial workplaces & large events.
- **Validation by Tier-1 Customers:** India Oil Corporation, with 33,000 employees worldwide, is evaluating the Safe Entry Station for a global rollout.
- **High-Margin, Recurring Revenue Model:** Screening as a Service (SaaS) model with recurring monthly revenue, software-like margins and multi-year contracts.
- **Remote Patient Care Platform:** Additional optionality to leverage AI tools and wearables to create a data-enabled remote monitoring telehealth platform.



Predictmedix	
CSE: PMED - OTCQB: PMEDF	
Share Price ¹	\$0.20
Market Cap ¹	\$21.9M
Quarterly Cash Usage	\$0.4M
Cash ²	\$1.7M
Debt ²	\$0
Shares Outstanding	108.8M
Headquarters	Toronto, CAN
1. At August 10, 2021	
2. As of April 30, 2021	




The Current Landscape




COVID-19 & Infectious Diseases



Workplace Cannabis & Alcohol Impairment



Mental Illnesses




Virtual Care



SAFE ENTRY STATION

Powered By: **PREDICTMEDIX**



Screening for Symptoms of COVID-19 & Infectious Diseases

Infections including COVID-19, produce unique physiological patterns that our solution will detect, assess and determine the probability of that person being infected or not infected.

As the virus mutates, our AI will learn how new symptoms present new patterns from which to continue detecting infection.

Predictmedix is critical even after an effective, safe vaccine has successfully been deployed to at least 80% of the global population in the coming years as annual flu and other infectious diseases proliferate

1

Quick, non-invasive, contactless screening

2


Fully automated without the need for personnel to operate

3

Indicates positive or negative result so safety protocols can be initiated

Easy to deploy in any indoor and outdoor location

Workplaces, Retail, Institutions & Buildings



Screening for Cannabis & Alcohol Impairment

Employers, as well as law enforcement, test people for traces of cannabis, alcohol and opioids. However, they cannot determine if individuals are actually impaired.

Without the ability to determine impairment, it is impossible to accurately predict safety risk, particularly for employees operating heavy machinery – which is ever more important as cannabis is now medically prescribed.

Rather than test for traces of potentially legal substances, Predictmedix uses multispectral recognition technologies and AI to screen for true impairment from these substances.

First to Market

Predictmedix first-to-market AI product screens for Cannabis impairment.

The Predictmedix AI model is being expanded to include screening for alcohol and opioids.

1


Quick, non-invasive, contactless screening

2

Fully automated without the need for personnel to operate

3

Indicates positive or negative result so safety protocols can be initiated



Mental Illness Diagnostic Screening

Mental illness is difficult to detect at early stages. Primarily due to a lack of diagnostic tools other than standardized surveys and subjective assessment from trained healthcare practitioners.

Predictmedix will use multispectral image patterns to effectively determine signs of mental illnesses, including depression, dementia and Alzheimer's

Predictmedix deployed in healthcare facilities and medical offices will provide practitioners with a simple, measurable diagnostic tool to detect signs of these disorders at early stages.

1

Quick, non-invasive,
contactless
screening

2

Fully automated
without the need for
personnel to operate

3

Indicates positive or
negative result so safety
protocols can be initiated

First Diagnostic Tool

Predictmedix Mental Illness Diagnostic Screening is a disruptive AI technology that will be the first solution of its kind to give healthcare practitioners the opportunity to provide proper care before their patients' condition worsens.

**Max Healthcare has
partnered with Predictmedix
to provide data for the
development of AI diagnostic
models for mental illness.**




Safe Entry Station Financial Model

Screening as a Service (SaaS)

Drives High-Margin, Recurring

Revenue with Multi-Year Contracts



Hardware Deployment \$3,500 – 12,000/Unit

Safe Entry Station fabricated by strategic partners, with gross profit margins of 30-50% depending on regional supply chains.



Recurring SaaS Fee \$1,000 – 3,000/month

Screening as a Service (SaaS) pricing per unit based on volume of screenings, providing predictable, high-margin revenue.



Multi-Year Contracts

Our customers invest in our technology not as a reaction to COVID, but with the long-term understanding that public health will never be viewed the same and that detecting infectious diseases or drug and alcohol impairment in the workplace has significant value.



Tier-1 Global Reseller Partnerships

The biggest and best believe in our solutions



Tech Mahindra – India Tier-1

Predictmedix has signed Joint Venture agreements with Tech Mahindra, who will resell Predictmedix to their global client base, having already participated in a successful pilot test with our team.

Top 15

GLOBAL IT COMPANIES BY FORBES

\$4.9B

COMPANY OWNED BY MAHINDRA GROUP, A \$420.7BN FEDERATION OF COMPANIES

North American Resellers

- Juiceworks Exhibits
- SBL Testing Technologies
- ConnectUs Global

European Resellers

- Taurus Medical (U.K.)

Caribbean Resellers

- Caribbean Digital Media Academy



Paras Defence – India Tier-2

Predictmedix secured a reseller agreement with Paras Defence, an Indian defense contractor, who will fabricate and sell the Company's products within the South Asian market.

India's Most Progressive Defense Company

Significant Public Sector Reach

Defense contractor leveraging established public sector relationships throughout Asia

Capital-light commercial model leverages immense reach of our tier-1 partners, while keeping operating costs low to minimize burn.






Safe Entry Station "PredictMedix" inauguration Indian Oil Corporation (IOCL)



Predictmedix Inc. and Juiceworks Provide
Safe Entry Solutions to Facility Managers at
IFMA World Workplace in Texas

PUBLISHED
SEP 3, 2020 8:00AM EDT



by @accesswire on 26 Jun 2020, 08:01

Predictmedix and Tech Mahindra to Offer AI Based
Healthcare Solution for Post COVID-19 Environment

Mobile Wellbeing – Next Gen Virtual Care

Remote patient monitoring & telehealth platform for healthcare, LTC and employers

Predictmedix has acquired Mobile Wellbeing (MWB) to provide screening clients with an end-to-end solution, and to leverage a rapidly growing market for remote care in hospital settings as well as for specific high value sectors, including:

Long Term Care (LTC) and Retirement Residences

Covid-19 has revealed the devastating shortfalls in elder care that can be addressed by MWB's tools, giving families transparency of care being delivered to their loved ones

Clinical Research Organizations (CRO)

Traditional methods of on-site monitoring for clinical studies of medicines and vaccines has been greatly obstructed due to the current pandemic, and can be better managed using MWB to provide rigorously detailed virtual oversight and compliance

Large Scale Employees

Existing human resource platforms cannot provide managed return-to-work programs for employees diagnosed with Covid-19 or other infectious diseases, which can be best facilitated through MWB's integration with PredictMedix Screening Products or as a stand-alone tool



Mobile Wellbeing

Putting care into telehealth

Predictmedix has partnered with Versus Systems to integrate Versus' proprietary rewards platform



Wearables and Bluetooth

Makes it easy for patients to share their vitals through the platform, and to give healthcare practitioners accurate, instant data to provide highly responsive care



Reward Programs

Incentivises compliance to promote better outcomes and a more enjoyable care experience



Engagement tools

From video to multiple communication channels, patients and practitioners, employees and HR professionals, will have comfortable ways to stay in touch and manage progress through care programs



Intellectual Property Portfolio

Protecting our Technology in Key Global markets

6 U.S. PATENTS HAVE BEEN FILED

IMPAIRMENT (1)

INFECTIOUS DISEASE SYMPTOMS (1)

MOBILE WELL-BEING (4)

Predictmedix Science Based Technology to Identify Persons Exhibiting Symptoms of Covid-19 and Other Infectious Diseases

July 6, 2020

Predictmedix is developing a proprietary Artificial Intelligence (AI) technology (patent pending) to identify persons who are presenting science-based symptomatic evidence of Covid-19, as well as other infectious diseases including Influenza.

The AI powered technology utilizes multispectral imaging cameras and ancillary sensors as data collection sources. These cameras and sensors provide the Predictmedix AI Covid-19 & Infectious Disease Screening Model with visual spectral imaging plus infrared thermography that falls outside of visual spectrum wavelengths. This data is processed using a Cloud/Edge configuration comparing, in real time, the complex thermographic patterns of persons being screening with learned data sets from healthy control groups and Covid-19 patients.

The result is an evidence-based determination that outputs a probability of infection or no infection. Built as an AI machine learning system, the Model continuously evolves as more data is received through screenings and from testing partners providing the most recent physiological patterns associated with symptoms of the virus. These include currently known symptoms of fatigue, headache, coughing, congestion, difficulty breathing and fever, which in turn have identifiable features based on blood flow, sweat gland activation, eye redness and other physiological processes.

As demonstrated by several studies, physiological patterns can be identified through multispectral cameras, and when used in proper combination can be used to assess the probability of an individual exhibiting symptoms associated with Covid-19 infection.

The utility of thermal imaging in identification of headaches has been explored in several studies over the past forty years. In 1997, Ford et. al. reviewed thermograms of 993 suitable patients with migraine with and without aura, chronic daily headache, cluster headache, posttraumatic headache, and a variety of other headache types.¹

Eight hundred fifty-five (86.1%) had abnormal thermograms usually characterized by decreased supraorbital thermal emission. Six hundred ninety-four (69.9%) of 993 had migraine without aura of whom 593 (85.4%) had abnormal thermograms. Two hundred two (20.3%) of 993 had migraine with aura, of whom 180 (89.1%) had abnormal thermograms. Thirty of 35 (85.7%) patients with cluster headache, and 28 of 33 (84.8%) with posttraumatic headache had abnormal thermograms. Twenty-four of 29 (82.8%) of patients with various less common headaches and head pain syndromes had abnormal thermography. The study concluded infrared thermography as being a useful diagnostic test in the management of headaches.

¹ Ford RG, Ford KT. Thermography in the diagnosis of headache. Semin Neurol. 1997;17(4):343-349. doi:10.1055/s-2008-1040947.

Page 1 of 3

Fatigue has adverse effects in both physical and cognitive abilities. Thermal imaging and facial analysis provide a mean to detect changes in the human body unobtrusively and in variant conditions of pose and illumination. Studies have demonstrated automatic detection of exercise-induced fatigue using thermal cameras and facial images, by analyzing them using deep convolutional neural networks. Furthermore, results indicate that classification of fatigued individuals is possible, obtaining an accuracy that reaches over 80% when utilizing single thermal images.⁹

Similarly, thermal imaging has also been explored as a tool for identification of nasal congestion. Moreover, studies have reported thermography as a better tool than X-rays in diagnosing frontal and ethmoidal sinusitis and as good as X-ray PNS and nose in diagnosing maxillary sinusitis.²

Ocular abnormalities consistent with keratoconjunctivitis³, commonly referred to as pink eye, as well as conjunctival hyperemia, chemosis, epiphora, or increased secretions⁴, have been shown to occur in patients with Covid-19.

Breathing function consists of inspiration and expiration cycles during which heat exchanges occur. The body generates a periodic or quasiperiodic thermal signal in between high (expiration) and low (inspiration) values. This imaging system at a distance, achieving an accuracy of

is usually positioned near the nostrils to capture this breath signal. Thermal imaging behaves therefore as a non-invasive process, but at a distance. The estimation of breathing rate is as proved by comparison with respiratory ground-truth [47,48]. Murthy et al¹⁰ found a high degree of chance correlation between the thermal and mechanical recordings over the same period.

Thermal imaging and visible and thermal imaging to monitor the breathing function. Thermal imaging of the nose and mouth detection through a cascade classifier tracking of these regions over time. ROIs coordinates were extracted from thermal video. In terms of breathing rate estimation, the proposed method and the Bland-Altman plot with 95% confidence interval [39].

In several studies to be a reliable way for estimating breathing rate using thermal imaging technology for screening symptoms associated with COVID-19.

The proposed method performance that includes both an increase in the breathing rate and an eventual inability to produce this force.

Thermography in the Diagnosis of Chronic Sinusitis. Cureus. 2020;12(7):e2298. doi:10.7755/cureus.2298. article/50008-4182(20)30305-7/pdf. Findings of Patients With Coronavirus Disease 2019 (COVID-19) in the Emergency Department. JAMA Ophthalmol. 2020;138(5):575-578. doi:10.1001/jamaophth.2020.1291. breathing function. IEEE Eng. Med. Biol. Mag. 2006; 25, 57-67. Rykisssoon, R.J.; Lucke, J.F.; Faiz, S.; Castriotta, R.J. Thermal infrared thermography. Sleep 2009; 32, 1521-1527. d for extracting respiration rate and relative tidal volume from infrared thermal imaging. X.K. Synergetic use of thermal and visible imaging techniques for non-invasive respiration rate estimation. J. Biomed. Opt. 2017, 22, 036006.

Page 2 of 3

to not determine symptomatic evidence of Covid-19

of the skin rather than temperature of the body. Skin factors as well as external factors including air circulation.

cold or hot weather will produce different skin temperature. If the person has been inside acclimatizing to the environment wears a heavy coat, for example, their sweat glands will be active. When removing their coat, the skin temperature for a period of time which is slightly different for each individual.

the absence of additional science-based symptomatic evidence of Covid-19. The proposed method may be used as a camera temperature check than would be by being screened by Predictmedix.

Healthcare Group (Bloomberg Press Release), one of the additional studies to be announced, will ensure that the detection abilities as newly discovered symptoms and biological effects are identified.

ing exercise-induced fatigue using thermal imaging and deep learning," in Proceedings of the 2017 IEEE International Conference on Systems, Man, and Cybernetics (SMC), Montreal, QC, 2017, pp. 1521-1527.

Page 3 of 3

Leadership Team



Sheldon Kales

CEO

- Expertise in operations, business strategy and capital markets
- Held leadership roles operating R&D companies in the USA, Canada and the Middle East
- Led companies from start-up stages through growth and successful exits



Dr. Rahul Kushwah

COO

- PhD, Banting Fellow (one of 23 global recipients in medicine)
- Developed world's first genetic test for cannabis pharmacogenetics
- Previously on the National Research Council for the Government of Canada in Human Health Therapeutics
- Expertise in human diseases, genetics, immunology and regenerative / personalized medicine



Rakesh Malhotra

CFO

- CPA designation in US and Canada, FCA
- Over 25 years in accounting, financing and internal controls
- Has held senior management positions in publicly traded companies



Nandan Mishra

Co-AI Lead

- Artificial Intelligence pioneer in translational research for AI
- Masters in Systems Biology and Bachelors Degree in Engineering from the Indian Institute of Technology
- Member of the prestigious National Mission of Interdisciplinary Cyber Physical Systems of India (a federal technology think tank)



Himanshu Ujjawal Singh

Co-AI Lead

- Specialization in Data Analytics and AI
- Consulted with several multinational corporations in setting up their analytics practice in the field of telecom, healthcare, retail and workforce analytics
- Expertise in data monetization



Rajiv Muradia

VP, Operations

- Mobile Wellbeing Founder
- Executive entrepreneur with experience in technology, management and business development
- Rajiv has successfully founded several companies and has helped a number of start-ups with their product strategy, positioning and technology visions



Future Outlook

There is a growing need for rapid, mass, early stage screening for governments, healthcare and employers.

We also see that the heightened environment of anxiety caused by the COVID-19 pandemic is accelerating adoption of these technologies.

AI powered technologies such as Predictmedix are positioned to eliminate the need for biologics and can be deployed anywhere without the need for onsite personnel to operate the solution.



COVID-19 & Infectious Disease Symptom Screening

- **Expand Revenue Base:** Large scale commercial rollouts in North America, Europe and India, currently in discussion phases
- **Improve Capabilities:** Completion of clinical study with MGM Hospital Group and active data collection and algorithm training to identify symptoms associated with new and emerging COVID variants
- **Multi-Variant Functionality:** Enhancement of AI models using clinical data to further advance multi-symptom detection



Drug & Alcohol Impairment Screening


- **Proof of Efficacy:** Completion of study with over 3,000 participants
- **Continual Improvement:** Refinement of AI models to improve impairment detection
- **Commercialization of Impairment Functionality:** Pilot programs with partners and new companies to be followed by aggressive commercial rollouts



Mobile Wellbeing Remote Care Platform

- **Complete Development:** Completion of upgraded development and sector specific features
- **Customize for Desired Niches:** Launch of platform versions for targeted sectors
- **Initiate Commercialization of AI-Enabled Remote Care Platform:** Pilot and rollout programs





PREDICTMEDIX

CSE : PMED OTCQB : PMEDF

PREDICTMEDIX.COM  

CORPORATE INFORMATION

77 King Street West, Suite 3000
Toronto, ON, Canada M5K 2A1

INVESTOR RELATIONS

Lucas A. Zimmerman
Director – MZ North America
(949) 259-4987
PMEDF@mzgroup.us



COVID-19 & Infectious Disease Symptom Screening

Competitive Landscape

Company	AI	Non-Invasive	Temperature Detection	Multi-Symptom Detection	Notes	Commercialization Stage
	✗	✓	✓	✗	Potentially introducing more symptom detection	Launching
	✗	✓	✓	✗	Indicates it is AI Enabled which may mean future versions will use AI in some fashion	Commercialized
	✗	✓	✗	✗	Tests air which means exposure potential already high	Commercialized
	✓	✓	✓	✓	AI powered symptom detection screening	Commercialized



Cannabis & Alcohol Impairment Screening

Competitive Landscape

Company	AI	Non-Invasive	Impairment Detection	Notes	Commercialization Stage
	✗	✗	✗	Breathalyzer	Pre-commercialization
 HOUND LABS™	✓	✗	✓	Unknown how it determines impairment and may rely on amount of cannabinoids to apply a rating for potential impairment similar to alcohol breathalyzer tests	Pre-commercialization
 PREDICT MEDIX	✓	✓	✓	Non-invasive screening that uses machine learning AI models to assess impairment unique to each individual	Product Development

Board of Directors



Sheldon Kales

- Expertise in operations, business strategy and capital markets
- Held leadership roles operating R&D companies in the USA, Canada and the Middle East
- Led companies from start-up stages through growth and successful exits



Dr. Rahul Kushwah

- PhD, Banting Fellow
- Developed world's first genetic test for cannabis pharmacogenetics
- Previously on the National Research Council for the Government of Canada in Human Health Therapeutics
- Expertise in human diseases, genetics, immunology and regenerative / personalized medicine



Ajit Kumar

- Seasoned healthcare business leader
- Founder of K-Med Ltd.; among the largest suppliers of healthcare and medical equipment in the UK with operations in the Middle East, EU and Africa



Tomas Sipos

- Seasoned investment banker
- Has held several senior positions, including VP, Mergers and Acquisitions of Ernst & Young, Managing Director of Investment Banking at European Privatization & Investment Corporation and Senior Investment Banker for the International Finance Corporation
- Presently, CFO for Pistil Partners Inc., and serves as a director of NATO Association of Canada Program Committee



Advisory Board

Kapil Raval

Advisory Board Chair
Director of AI, Business Development, Microsoft

Global Business Leader with 25+ years experience. Kapil is currently a director at Microsoft, driving business development for AI solutions for different industries globally.

Having worked for global organizations like Philips, DEC, Compaq and HPE and Microsoft in Americas, Middle East and APJ, Kapil brings understanding of global cultural and market nuances, inventiveness and problem-solving skills.

Prabhakar Srivastava

Business Development

Senior Healthcare Executive with over 38+ years experience including CEO of an Indo-Israeli Venture. Mr. Srivastava has been pivotal in launching state-of-the-art innovative solutions for indigenous production through Transfer of Technology in healthcare & environment fields from companies including Phillips Medical Systems, Picker International Inc, Elscint Ltd., Medison Co. Ltd. and Toshiba Corporation.

Additionally, he has served as advisor to several African Countries viz. Uganda, Republic of Burundi & Federal Republic of Nigeria along with the government of India.

Dr. Deepu Banerji MSc, PhD

- Neurosurgeon with over 34 years' experience in microscopic and minimal invasive neurosurgery
- Sugita Fellow from Nagoya University, Japan for micro neuro-surgical training
- Consistently ranked amongst the top 5 neurosurgeons in India.

Dr. Indranil Saha PhD

- Assistant Professor, Computer Science & Engineering, IIT
- Expert in the areas of Artificial Intelligence and Robotics
- Received the ACM SIGBED Frank Anger Memorial Award in 2012 for his contribution in the intersection of embedded systems and software engineering

Dr. Nitin Kadam MBBS, DHC, MD

- Professor at M.G.M. Medical College Mumbai
- Management team member for M.G.M. group of colleges and hospitals
- Director of M.G.M.'s New Bombay Hospital
- Management Council Member, M.G.M. University of Health Sciences, Academic Council & Board of Studies

Dr. Dawn Decunha

- Clinical Psychologist and educator
- Specialty in emotional trauma, psychiatric and psychological trauma

Kiran Kkumari

- Senior oil and gas executive who has assisted some of the largest multinational conglomerates with business development in Asia.

Dr. Navdeep Singh Nanda MBBS, MS, DNB

- One of India's leading thoracic surgeons, practicing in BLK Super Speciality Hospital, the largest stand-alone private sector hospital in India
- Immense experience in the field of thoracic surgery, thoracic oncology, VATS, robotic chest surgery and related research

Dr. Mike Hart MD

- Early adopter of medicinal marijuana applications in medical practice, opening first of its kind facility in London, Ontario
- "Expert" guest on the subject of medicinal marijuana, appearing on CTV news, Rogers TV, CBC National Radio, Toronto Star and Canadian Consortium for the Investigation of Cannabinoids

Dr. Alexander D. Bardon CCFP(EM)

- Emergency Room physician for over 6 years
- Expertise in infectious disease and screening
- Works in 3 different hospital emergency departments: Norfolk General, St. Mary's General and Grand River Hospital
- Associate Clinical Professor at McMaster University

Dr. Tally Bodenstein PhD

- Practicing psychologist for over 20 years
- Speciality in children, adolescents and families

